Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIC - WACC | (270.7%) | (311.8%) | (242.6%) | (463.5%) | (827.8%) | (210.3%) | (128.0%) | 5.5% | (9.3%) | (65.1%) | (86.7%) | (54.4%) | (6.1%) | 13.0% | 165.3% | 38.0% | 65.6% | 55.4% | 72.2% | 65.9% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month ROIC - WACC is (23.4%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual ROIC - WACC for Vertex Pharmaceuticals Incorporated have been 45.7% over the past three years, and 53.8% over the past five years.
As of today, Vertex Pharmaceuticals Incorporated's ROIC - WACC is (23.4%), which is higher than industry median of (127.8%). It indicates that Vertex Pharmaceuticals Incorporated's ROIC - WACC is Good.